INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow
A review of the past, present and future of the hepatitis C market – by the numbers.
You may also be interested in...
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition
In interview with the Pink Sheet, US FDA Commissioner Scott Gottlieb offers a final reflection of his time as commissioner.
While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.